Physiogenex

Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, ...) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making

Preclinical services,cro,pharmacology services,animal models,metabolic syndrome,diabesity,dyslipidemia,non alcoholic steatohepatitis,nash,liver diseases,atherosclerosis,type 2 diabetes,obesity,in vivo efficacy models,and ex vivo assays

Physiogenex operates in the Research industry.

Physiogenex's revenue is 1m - 10m

Physiogenex has 11 - 50 employees.